The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Syndrome

Background:

• Hepatocellular carcinoma (HCC) is a major cause of cancer mortality.
• Obesity, cirrhosis, and chronic hepatitis are key risk factors for HCC.
• The molecular pathways driving HCC development are not fully understood.

Purpose of the Study:

• To investigate the role of the deubiquitinase USP30 in HCC development.
• To elucidate the molecular mechanisms linking obesity and HCC.
• To identify potential therapeutic targets for HCC.

Main Methods:

• Analysis of USP30 expression in HCCs from high-fat diet-fed mice.
• Investigating the interaction between IKKβ, USP30, ACLY, and FASN.
• Assessing the impact of USP30 deletion on HCC development in mice.
• Evaluating the efficacy of combined ACLY inhibitor and PD-L1 antibody therapy.

Main Results:

• USP30 is upregulated in diet-induced HCCs and deubiquitinates ACLY and FASN.
• IKKβ stabilizes USP30 and enhances ACLY deubiquitination.
• USP30 deletion reduces lipogenesis, inflammation, and tumorigenesis in mice.
• The IKKβ-USP30-ACLY axis is upregulated in human HCCs.
• Combined ACLY inhibition and PD-L1 blockade suppressed chemical-induced hepatocarcinogenesis.

Conclusions:

• The IKKβ-USP30-ACLY axis is a critical regulator of tumor metabolism in HCC.
• This pathway is implicated in HCC development across different models, including diet-induced and chemical-induced.
• The IKKβ-USP30-ACLY axis represents a promising therapeutic target for HCC.